Nonomura, Y.; Nakayama, K.; Nakamura, K.; Razia, S.; Yamashita, H.; Ishibashi, T.; Ishikawa, M.; Sato, S.; Nakayama, S.; Otsuki, Y.;
et al. Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents. Healthcare 2022, 10, 694.
https://doi.org/10.3390/healthcare10040694
AMA Style
Nonomura Y, Nakayama K, Nakamura K, Razia S, Yamashita H, Ishibashi T, Ishikawa M, Sato S, Nakayama S, Otsuki Y,
et al. Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents. Healthcare. 2022; 10(4):694.
https://doi.org/10.3390/healthcare10040694
Chicago/Turabian Style
Nonomura, Yuki, Kentaro Nakayama, Kohei Nakamura, Sultana Razia, Hitomi Yamashita, Tomoka Ishibashi, Masako Ishikawa, Seiya Sato, Satoru Nakayama, Yoshiro Otsuki,
and et al. 2022. "Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents" Healthcare 10, no. 4: 694.
https://doi.org/10.3390/healthcare10040694
APA Style
Nonomura, Y., Nakayama, K., Nakamura, K., Razia, S., Yamashita, H., Ishibashi, T., Ishikawa, M., Sato, S., Nakayama, S., Otsuki, Y., & Kyo, S.
(2022). Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents. Healthcare, 10(4), 694.
https://doi.org/10.3390/healthcare10040694
